Trial Profile
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 11 Feb 2020 Results published in the Vaccine
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 26 Apr 2016 Status changed from recruiting to active, no longer recruiting.